Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis

James, Deepak; Jena, Anuraag; Bharath, Pardhu Neelam; Choudhury, Arup; Singh, Anupam; Sebastian, Shaji; Sharma, Vishal

doi:10.1016/j.dld.2022.03.005

Cited by 21 publications

(19 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are consistent with those of the recent meta-analysis of studies of the safety of severe acute respiratory syndrome coronavirus 2 vaccination in patients with IBD (34), showing as they do no increase in flare risk. In contrast to the 6 small cohorts comprising 4,537 patients and 75 flares reported there though, our report represents the experience of 73,626 patients with IBD with documented vaccination among whom 1,940 experienced a flare at some time during the study period.…”

Section: Discussionsupporting

confidence: 93%

“…Though we cannot exclude this we feel that such minor effects would be unlikely to greatly discourage vaccination uptake and that it is the more significant flares which we have studies which are the primary concern. Research in context: Our findings are consistent with those of the recent metaanalysis of studies of the safety of SARS-CoV-2 vaccination in IBD patients (34),…”

Section: Discussionsupporting

confidence: 91%

“…In contrast to the 6 small cohorts comprising 4,537 patients and 75 flares reported there though, our report represents the experience of 73,626 patients with IBD with documented vaccination among whom 1,940 experienced a flare at some time during the study period. In addition, rather than reporting the absolute flare incidence post-vaccination (flare probability 0.01 [95% CI 0.01–0.03] (34)), we have reported an incidence rate ratio comparing the risk in periods after vaccination with patients' experience at other times (IRR 0.89 [95% CI 0.77–1.02]). Of the patients in the studies included in meta-analysis cited earlier, most of them (n = 3,316) came from a single study reporting a US cohort study, ascertaining data through repeated survey of participants (35).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Previous clinical studies have linked the development of ulcerative colitis to reduced NF-κB1 expression because of pathological variants. Generally, immunosuppressants and/or anti-TNF-α antibodies are commonly used to treat patients with ulcerative colitis [ 15 , 16 , 17 ]. Therefore, it has been established that the antivirus antibody production in response to vaccines, including the COVID-19 mRNA vaccine, is lower in patients with ulcerative colitis than in healthy subjects.…”

Section: Discussionmentioning

confidence: 99%

Spontaneous Myocarditis in Mice Predisposed to Autoimmune Disease: Including Vaccination-Induced Onset

2022

View full text Add to dashboard Cite

Nonobese diabetic (NOD)/ShiLtJ mice, such as biobreeding rats, are used as an animal model for type 1 diabetes. Diabetes develops in NOD mice as a result of insulitis, a leukocytic infiltrate of the pancreatic islets. The onset of diabetes is associated with moderate glycosuria and nonfasting hyperglycemia. Previously, in NOD/ShiLtJ mice spontaneously developing type 1 diabetes, the possible involvement of decreased expression of nuclear factor-kappa B1 (NF-κB1) (also known as p50) in the development of type 1 diabetes was investigated. In response to these arguments, NOD mice with inconsistent NF-κB1 expression were established. Surprisingly, the majority of NOD Nfκb1 homozygote mice were found to die by the eighth week of life because of severe myocarditis. The incidence of spontaneous myocarditis in mice was slightly higher in males than in females. Furthermore, insulitis was observed in all NOD Nfκb1 heterozygote mice as early as 4 months of age. Additionally, in NOD Nfκb1 heterozygote mice, myocarditis with an increase in cTnT levels due to influenza or hepatitis B virus vaccination was observed with no significant gender difference. However, myocarditis was not observed with the two types of human papillomavirus vaccination. The results of immunological assays and histopathological examinations indicated that vaccination could induce myocarditis in genetically modified mice. In this study, we report that NOD Nfκb1 heterozygote mice can be used for investigating the risk of myocarditis development after vaccination.

show abstract

“…Gráfico 1 Número de pacientes vacunados con la primera, segunda y tercera dosis. En este estudio se observó cómo los efectos adversos en pacientes con LES son leves, en concordancia con otros reportes 13 . Respecto a los efectos adversos más frecuentes que se identificaron en la presente investigación, se encontró un predominio del dolor, fiebre y la fatiga.…”

Section: Discussionunclassified

Frequencies of adverse events following COVID-19 vaccination in patients with Systemic Lupus Erythematosus Erythematosus in a referral center in Asuncion-Paraguay

Martinez

Weiler²,

Rojas³

et al. 2022

Rev. parag. reumatol

View full text Add to dashboard Cite

Fecha de envío 18/04/22 Fecha de aprobación 10/05/22 Palabras claves eventos adversos, vacuna, COVID-19, Lupus ResumenEl objetivo de este estudio es determinar la frecuencia de eventos adversos de la vacunación contra el COVID-19 en pacientes con LES que son atendidos en centros médicos de referencia en Paraguay. Este es un estudio observacional, transversal, descriptivo. Se incluyeron 52 pacientes con LES que recibieron al menos una dosis de la vacuna anticovid. De los cuales el 100% recibieron la primera dosis, el 92,3% la segunda dosis y el 15,38% la tercera dosis; el 44,6% recibió Sputnik-V; 16% Moderna; 12,5% Pfizer, 7,1% AstraZeneca, 3,6% Covaxin y 2,1% Hayat Vax, 8 pacientes recibieron su tercera dosis correspondiente a 3 de Pfizer, 3 de Moderna, 2 de AstraZeneca. En las 108 dosis aplicadas se registraron un total de 43 evento advserso, el 95,3% dentro de los primeros 5 días y el resto a los 5 días. El 51,2% presentó el evento advserso tras la primera dosis, el 39,5% tras la segunda dosis y el 9,3% tras la tercera dosis. La duración media de los síntomas fue de 2,3 días ±1,4. El efecto adverso más importante fue el dolor en el sitio de inyección, seguido de fiebre y fatiga. La exacerbación del LES también se registró como evento advserso en el 8,3%. Se registraron efectos adversos leves, se concluye que vacunación contra covid 19 es segura para pacientes con LES. Frequencies of adverse events following COVID-19 vaccination in patients with systemic Lupus erythematosus erythematosus in a referral center in Asuncion-Paraguay

show abstract

Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis

Cited by 21 publications

References 53 publications

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD

Spontaneous Myocarditis in Mice Predisposed to Autoimmune Disease: Including Vaccination-Induced Onset

Frequencies of adverse events following COVID-19 vaccination in patients with Systemic Lupus Erythematosus Erythematosus in a referral center in Asuncion-Paraguay

Contact Info

Product

Resources

About